118 related articles for article (PubMed ID: 16337037)
1. New insights into molecular mechanisms of diffuse coronary ectasiae: a possible role for VEGF.
Savino M; Parisi Q; Biondi-Zoccai GG; Pristipino C; Cianflone D; Crea F
Int J Cardiol; 2006 Jan; 106(3):307-12. PubMed ID: 16337037
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
3. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
5. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
7. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
8. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
[TBL] [Abstract][Full Text] [Related]
9. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
Kolomecki K; Stepien H; Bartos M; Kuzdak K
Endocr Regul; 2001 Mar; 35(1):9-16. PubMed ID: 11308991
[TBL] [Abstract][Full Text] [Related]
13. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction.
Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Clark LT; Pinsky DJ; Marmur JD
Am Heart J; 2006 May; 151(5):1101.e1-8. PubMed ID: 16644343
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals.
Randeva HS; Lewandowski KC; Komorowski J; Murray RD; O'Callaghan CJ; Hillhouse EW; Stepien H; Shalet SM
Circulation; 2004 May; 109(20):2405-10. PubMed ID: 15123527
[TBL] [Abstract][Full Text] [Related]
16. MMP and TIMP alterations in asymptomatic and symptomatic severe recurrent carotid artery stenosis.
Sapienza P; Borrelli V; di Marzo L; Cavallaro A
Eur J Vasc Endovasc Surg; 2009 May; 37(5):525-30. PubMed ID: 19297218
[TBL] [Abstract][Full Text] [Related]
17. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
[TBL] [Abstract][Full Text] [Related]
18. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
[TBL] [Abstract][Full Text] [Related]
19. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
20. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
